A combination regimen may be effective in patients with relapsed or refractory multiple myeloma and moderate to severe renal impairment, especially in those with advanced disease requiring hemodialysis.
Patients with relapsed or refractory multiple myeloma should be given individualized treatment based on numerous factors, including biology of the disease and type of relapse, according to a presentation at the 12th Annual National Comprehensive Cancer Network (NCCN) Congress: Hematologic Malignancies (October 6-7, 2017; San Francisco, CA).
Results of eight recent clinical trials show that older patients treated for relapsed or refractory multiple myeloma with novel therapies had similar rates of progression-free survival (PFS) as younger patients.
The analysis was presented at the 2017 European Society for Medical Oncology Congress (September 8-12, 2017; Madrid, Spain).
Daratumumab-based combination therapies (DCTs) are ineffective in patients with multiple myeloma who have been heavily pre-treated or are refractory to one or more agents in a DCT, according to a recent study published in American Journal of Hematology (online August 11, 2017; doi:10.1002/ajh.24883).
NEW YORK (Reuters Health) - Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) prolongs the time to remission in patients with multiple myeloma (MM), according to an updated analysis of the CALGB 100104 phase 3 trial.
Carfilzomib, in combination with lenalidomide and dexamethasone (KRd), may be a cost-effective treatment option for patients with relapsed or refractory multiple myeloma, according to the Kyprolis Global Economic Model (K-Gem).